Boston Scientific Corporation $BSX Shares Purchased by Impax Asset Management Group plc

Impax Asset Management Group plc increased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 19.2% during the third quarter, Holdings Channel reports. The fund owned 1,727,380 shares of the medical equipment provider’s stock after acquiring an additional 277,644 shares during the quarter. Impax Asset Management Group plc’s holdings in Boston Scientific were worth $168,644,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. Steph & Co. purchased a new stake in shares of Boston Scientific in the third quarter valued at $25,000. Financial Consulate Inc. acquired a new stake in Boston Scientific in the 3rd quarter worth about $25,000. FWL Investment Management LLC acquired a new stake in Boston Scientific in the 2nd quarter worth about $26,000. United Community Bank grew its holdings in Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 147 shares during the period. Finally, Kilter Group LLC acquired a new position in shares of Boston Scientific during the 2nd quarter valued at about $30,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. This trade represents a 42.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on BSX shares. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $112.00 price target on shares of Boston Scientific in a research report on Friday. Morgan Stanley lowered their price objective on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. JPMorgan Chase & Co. cut their target price on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Citigroup lowered their price target on Boston Scientific from $130.00 to $102.00 and set a “buy” rating for the company in a research report on Thursday, February 5th. Finally, Evercore dropped their price target on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $109.43.

Boston Scientific Trading Up 0.2%

Shares of BSX opened at $74.26 on Wednesday. Boston Scientific Corporation has a one year low of $73.92 and a one year high of $109.50. The stock has a 50-day moving average price of $92.36 and a 200 day moving average price of $98.24. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. The company has a market capitalization of $110.09 billion, a P/E ratio of 38.28, a P/E/G ratio of 1.55 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.96%. The firm had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. During the same period in the prior year, the company posted $0.70 earnings per share. The firm’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Sell-side analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.